Data-Driven Mathematical Model of Apoptosis Regulation in Memory Plasma Cells

Philipp Burt 1,2, Rebecca Cornelis 1, Gustav Geißler 1,2, Stefanie Hahne 1, Andreas Radbruch 1, Hyun-Dong Chang 1,3,* and Kevin Thurley 1,2,4,*

1 German Rheumatism Research Center, 10117 Berlin, Germany; philipp.burt@drfz.de (P.B.); rebecca.cornelis@drfz.de (R.C.); gustav.geissler@gmail.com (G.G.); stefanie.hahne@drfz.de (S.H.); radbruch@drfz.de (A.R.)
2 Institute for Theoretical Biology, Humboldt University, 10115 Berlin, Germany
3 Institute of Biotechnology, Department of Cytometry, Technische Universität, 10623 Berlin, Germany
4 Biomathematics Division, Institute of Experimental Oncology, University Hospital Bonn, 53127 Bonn, Germany
* Correspondence: chang@drfz.de (H.-D.C.); kevin.thurley@uni-bonn.de (K.T.)

Abstract: Memory plasma cells constitutively produce copious amounts of antibodies, imposing a critical risk factor for autoimmune disease. We previously found that plasma cell survival requires secreted factors such as APRIL and direct contact to stromal cells, which act in concert to activate NF-κB- and PI3K-dependent signaling pathways to prevent cell death. However, the regulatory properties of the underlying biochemical network are confounded by the complexity of potential interaction and cross-regulation pathways. Here, based on flow-cytometric quantification of key signaling proteins in the presence or absence of the survival signals APRIL and contact to the stromal cell line ST2, we generated a quantitative model of plasma cell survival. Our model emphasizes the non-redundant nature of the two plasma cell survival signals APRIL and stromal cell contact, and highlights a requirement for differential regulation of individual caspases. The modeling approach allowed us to unify distinct data sets and derive a consistent picture of the intertwined signaling and apoptosis pathways regulating plasma cell survival.

Keywords: plasma cells; mathematical model; apoptosis; immunological memory; cell signaling

1. Introduction

The vertebrate immune system has the unique ability to provide long-term protection against pathogens it has encountered previously. An important cellular correlate of this long-term immunity is the long-lived memory plasma cell, which constitutively secretes copious amounts of specific antibodies. Antibodies produced by memory plasma cells serve as a highly efficient barrier against re-infection with pathogens, but have also been associated with a variety of autoimmune diseases [1–3]. Memory plasma cell survival is conditional on signals provided to them in dedicated survival niches, organized by mesenchymal stromal cells, most prominently in the bone marrow, where memory plasma cells can survive for decades [1,3–6]. The survival of memory plasma cells is mediated through the integration of multiple input signals, including integrin-mediated contact to mesenchymal stromal cells and signaling via B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI) [7,8]. In vivo, memory plasma cells can persist for a lifetime, i.e., they do not have a dedicated half-life: data indicate that plasma cells survive as long as they are provided with their niche [9–11].

Recently, we developed an in vitro culturing system for the study of plasma cell apoptosis [12]. We demonstrated that provision of A proliferation-inducing ligand (APRIL), addressing BMCA, and cell contact to the stromal cell line ST2, maintains primary bone marrow memory plasma cells in vitro for several days, thus preventing the rapid apoptosis...
process observed in absence of those factors [12]. Our in vitro system cannot yet reflect the very long in vivo survival times of plasma cells, which we think is mainly due to technical limitations—the co-cultured ST2 cells start overgrowing the plasma cells after ~5 days in culture. Nevertheless, we could show that APRIL and stromal cell contact act via different signaling pathways, namely, via nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) and phosphatidylinositol 3-kinase (PI3K), and address different cellular stress pathways, namely, endoplasmic reticulum stress and mitochondrial stress, respectively.

The wiring and control properties of the network at the interface of plasma cell death and extracellular factors such as APRIL and ST2 remain poorly understood. A prominent regulatory mechanism restricting the lifespan of plasma cells is the widely studied Bcl-2-associated X protein (BAX)-dependent apoptosis pathway [13], which ultimately results in the activation of caspases, a family of cysteine proteases. The complexity of the apoptotic network and the design principles leading to the apoptosis decision have been investigated extensively both by experiment and mathematical models [14,15], showing that caspase activation in single cells is rapid and irreversible [16,17], and that the apoptosis decision is well-described by a bi-stable and reversible switch [18–21]. However, it is less clear how different anti-apoptotic extracellular input signals affect the delicate machinery of cell death, and how well cell-type-specific aspects are captured by those modeling frameworks.

Here, we developed a mathematical model of plasma cell survival in the bone marrow, using published [12,22] and yet unpublished data on key components of the plasma cell apoptosis pathway. To this end, we started from a core model based on established principles of the BAX-dependent apoptosis pathway, by adding the extracellular input signals APRIL and ST2 cells, and subsequently, by considering a more detailed interaction network of several caspase proteins downstream of the BAX-module. We found that the survival factors APRIL and ST2 cells have differential rather than additive roles in the regulation of plasma cell lifespan extension, acting in different ways and primarily on different parts of the network. Further, our analysis underlines the essential aspect of differential caspase regulation for the apoptosis decision and provides insight into the parameters that could be manipulated to alter plasma cell lifespan.

2. Materials and Methods

2.1. Cell Culture and Flow-Cytometric Measurements of Apoptosis Proteins

Experiments were performed with the same cell culture system as previously reported [12]. In brief, mice were primed with 100 µg 4-hydroxy-3-nitropheylacetyl hapten-coupled chicken gamma globulin (NP-CGG) in incomplete Freud’s Adjuvants (IFA) intraperitoneally (i.p.). Mice were challenged twice after the prime with the same injection in cycles of 21 days. Plasma cells were magnetically isolated from immunized mice more than 30 days after the 2nd boost using a two-step protocol, including depletion of B220- and CD49b-expressing cells and subsequent positive enrichment of CD138<sup>high</sup> PCs. Isolated long-lived PCs from the bone marrow were cultured in RPMI1640 medium supplemented with 10% FCS, 100 U/mL Penicillin, 100 mg/mL streptomycin, 0.1% b-Mercaptoethanol, 25 mM HEPES buffer, and with/out 50 ng/mL multimeric APRIL. Cultures were kept under physiological oxygen levels in a hypoxia chamber with 4.2% O<sub>2</sub> and 5% CO<sub>2</sub> at 37 °C. The medium was changed at day 3 of culture. For the co-culture, 2500 ST2 cells were seeded in a 96-well plate one day before memory plasma cell isolation. Memory plasma cells were plated on top of the ST2 cell layer in a 1:1 ratio (5000 PC and 5000 ST2 cells). For analysis, cells were either fixed with PFA or stained directly and scraped off the plate before measurement.

Intracellular antigens were stained by fixing cells with PFA and permeabilization with methanol. To prevent unspecific binding, cells were pre-incubated with blocking buffer and subsequently stained with primary antibody for 1 h and, if necessary, with secondary antibody for 30 min (cf. Table 1). Samples were analyzed using a MacsQuant analyzer and FlowJo software. The following antibodies were used in the experiments:
Table 1. Antibodies used for flow-cytometric measurement of apoptosis proteins.

| Antibody Clone       | Manufacturer       | Catalog nr.     |
|----------------------|--------------------|-----------------|
| Anti-mouse BCL-2, REA356 | Miltenyi Biotec    | Catalog # 130-105-474 |
| Anti-mouse BIM, 14A8    | Milipore           | Catalog # MAB17001 |
| Anti-mouse CD138, REA104 | Miltenyi Biotec    | Catalog # 130-102-318 |
| Anti-mouse MCL-1, Y37   | Abcam              | Catalog # ab32087 |
| Anti-mouse NOXA, 114C307 | Abcam             | Catalog # ab13654 |

2.2. Data Analysis and Statistics

To estimate the half-life for plasma cells under different conditions, we fitted an exponential decay function \( f(t) = 100e^{-\lambda t} \) to each individual time series. The resulting decay rates were converted to half-lives for each condition according to: \( t_{1/2} = \log(2)/\lambda \), where \( \lambda \) represents the average decay rate summarized from the individual fit procedures. To compare average protein concentrations, geometric means for each protein measured under a specific condition were first normalized to the respective medium condition and then compared using an unpaired Student’s \( t \)-test. Uncertainties of protein ratios were calculated from the normalized protein concentrations by bootstrapping. To this end, we repeatedly drew from the original samples with replacement to estimate mean and standard deviation of the data.

2.3. Mathematical Models and Numerical Simulations

A complete description of the model equations is available as Supplemental Text S1. In brief, the model consists of two parts:

(a) **BAX-dependent apoptosis**: We consider (i) production and degradation of MCL-2 family proteins in dependence of the input stimuli APRIL and ST2, (ii) complex formation between pro- and anti-apoptotic proteins, and (iii) a dependence of the average half-life of the plasma cell population on the average concentration of activated BAX (BAX*) as follows:

\[
\lambda = \gamma \frac{[\text{BAX}^*]^3}{K_{\text{Bax}}^3 + [\text{BAX}^*]^3}.
\]

(b) **BAX-independent regulation of caspases**: To consider the effect of direct caspase regulation by APRIL and ST2 on the apoptosis decision, we extended the BAX-Apoptosis model and assumed additional regulation of the cell-death rate \( \lambda \) as follows:

\[
\lambda = \left[ \gamma \left( \frac{[\text{BAX}]^3}{K_{\text{Bax}}^3 + [\text{BAX}]^3} + \frac{\kappa}{1 + \alpha f([\text{APRIL}])} \right) \right] \left( \frac{1}{1 + \beta f([\text{ST2}])} \right).
\]

That means that the cell-death rate \( \gamma \) is increased due to the activity of caspase 3/7, which is induced through a combination of BAX-dependent and independent effects. Those BAX-independent effects stem from activity of caspase 12, which can be inhibited by APRIL. Finally, the activity of caspase 3/7 can be inhibited by ST2. Here, the fitting parameter \( \kappa \) is the relative effect of caspase 12 activity, the fitting parameter \( \beta \) denotes the maximal inhibitory effect ST2 on caspase 3/7, and we set \( \alpha = 10 \) for the inhibitory effect size of APRIL. For model fitting to our data in absence and presence of APRIL and ST2, we adopt a Boolean formulation for the regulatory function, \( f(x) = \begin{cases} 1, & x > 0 \\ 0, & x = 0 \end{cases} \). Modification of this function into a more specific Hill-type form such as \( f(x) = x^n/(x^n + K) \) is straightforward.

All model simulations were carried out in Python 3.8. Ordinary differential equations were solved using the scipy.odeint routine. For curve-fitting, least-squares optimization was employed using the Levenberg–Marquardt algorithm implemented in the Python lmfit library with the cost function \( \chi^2 = \sum_{i=1}^{N} \left( \frac{y_i - f(x_i)}{\sigma_i} \right)^2 \), where \( f(x_i) \) represents model
predictions, $y_i, \sigma_i$ represent measured data and data uncertainties, respectively, and $N$ denotes the number of data points.

For the calculation of AIC, we used the convention $AIC = 2k + N \ln(\chi^2 / N)$, where $k$ represents the number of fit parameters. For the perturbation analysis, we defined the effect size as the log2-fold change in half-life (or $BAX^*$) between a model simulation with best-fit parameter values and the model simulation with perturbed parameters. The parameters were either up- or downregulated by 2-, 5-, or 10-fold variation of the best-fit parameter value.

3. Results

3.1. A Quantitative Model of BAX-Dependent Apoptosis in Plasma Cells

Previous experiments have shown that plasma cells are not intrinsically long-lived but that provision of the cytokine APRIL combined with cell–cell contact, conferred by the stromal cell line ST2, keeps them alive in vitro for several days. Each factor alone proved to be insufficient to prevent rapid apoptosis [12] (Figure 1A). Re-plotting the data from Cornelis et al. [12] separately for individual experiments revealed an exponential survival curve for cultured plasma cells, where the half-life is significantly increased from less than 1 day to more than 6 days after addition of APRIL and ST2 (Figures 1B,C and S1). How these signals integrate and affect the underlying complex regulatory network facilitating apoptosis decisions remains unclear (Figure 1A). In particular, we wondered whether the experimental observations could be reconciled with an additive model, where APRIL and ST2 synergistically act to inhibit BAX-dependent apoptosis, or alternatively, whether APRIL and ST2 address fundamentally distinct parts of the apoptosis network.

Figure 1. Regulation of plasma cell survival via APRIL and ST2. (A) Schematic signal integration of ST2 and APRIL. How the signals are integrated into the BAX-dependent apoptosis network is yet unclear. Time course data were taken from Ref. [12] and are here represented as Box plots. Data were fitted to exponential curves, each experiment at a time (Supplementary Figure S1). Curves shown here represent mean + s.e.m. of those fit results. $BAX^*$ denotes activated BAX. (C) Average half-lives of each condition based on the fitting procedure from (B). ** $p < 0.01$, *** $p < 0.001$, n > 12 fits per condition. Error bars represent standard deviation.
In plasma cells, APRIL stimulates the NF-κB signaling pathway [12,23–25] and ST2 acts via the PI3K pathway to stimulate the transcription factor Forkhead-Box-Protein O1/3 (FoxO1/3), as shown by a series of targeted inhibition experiments [12,26]. Therefore, we started our analysis based on the working hypothesis that ST2 and APRIL act by targeting components of the BAX-dependent apoptosis pathway. In brief, oligomerization of two proteins, BAX and BAK (BCL-2-antagonist/killer 1), that are localized at the mitochondrial outer membrane and cytosol, leads to the formation of the apoptotic pore. Pore formation precedes cytochrome c and apoptosis-inducing factor release into the cytosol and downstream activation of caspases. The BCL-2 family comprises a group of proteins that is critical for the control of apoptosis by regulating the oligomerization of BAX and BAK. Localized mainly at the mitochondria, they can be divided into pro- and anti-apoptotic proteins. The anti-apoptotic proteins (B-cell lymphoma 2, BCL-2 and myeloid cell leukemia 1, MCL-1) prevent apoptotic pore formation and preserve the integrity of the mitochondrial membrane by binding to BAX and BAK. Pro-apoptotic proteins (Bcl-2-like protein 11, BIM, and NOXA), next to BAX and BAK, compete in binding to the anti-apoptotic proteins, thereby neutralizing them. Thus, the ratio of pro- to anti-apoptotic proteins plays a decisive role in apoptosis regulation [27]. The expression of the anti-apoptotic proteins BCL-2 and MCL-1 was shown to be upregulated in plasma cells, but while BCL-2 seems to be dispensable for the maintenance of memory plasma cells, MCL-1 is essential for their survival [28].

In multiple myeloma, MCL-1 strongly binds to BIM, thereby blocking apoptosis [29]. In addition to BIM, MCL-1 was reported to interact with NOXA [30].

To derive a mathematical model capturing those processes specifically for memory plasma cells, we measured the abundance of several key components of the BCL-2 family, namely, BIM, BCL-2, NOXA, and MCL-1, after 3 days in our established in vitro culture system [12] with and without stimulation by APRIL and ST2, by immune-fluorescent single-cell staining (Figure 2A). We found that ST2 cells had a significant negative effect on BIM, NOXA, and MCL-1 concentrations, whereas for APRIL alone, no significant effects could be detected. The divergent effects of APRIL and ST2 cells on different members of the BCL-2 family were far more pronounced when considering the ratios within pairs of pro- and anti-apoptotic proteins (Figure 2B). Taking that into account, we also considered upregulation of BCL-2 via APRIL stimulation as a plausible mechanism, although it was not significant at direct comparison (Figure 2A).

We used the information gained by experiments to establish a refined regulatory network of BAX-dependent plasma cell apoptosis (Figure 2C). Combined with a recently published compilation of quantitative data for the BCL-2 interactome (Table 2) [22,31–34], we were now in a position to formulate and annotate a specific mathematical model of BAX-dependent apoptosis in plasma cells (Methods and Supplementary Text S1). The only parameters lacking good estimates from the literature are the values describing protein production rates, which we therefore used as fitting parameters. Indeed, the resulting model was able to describe the new data set of BCL-2 family member protein abundance (Figure 2D).

Having established a mathematical formulation of the BAX-dependent apoptosis pathway in the context of plasma cell survival, we proceeded to the original question of whether APRIL- and ST2-dependent regulation of that pathway are sufficient to explain the observed survival kinetics shown in Figure 1B. Interestingly, we found that our model was well able to fit the protein and survival data individually (Supplementary Figure S2), but it was not able to capture both protein and survival data at the same time within the expected range of the experimental data (Figure 2E). In fact, the annotated model predicted a positive regulatory effect of ST2 on the average level of activated BAX (BAX*) in the plasma cell population (Figure 2F). That ST2-dependent elevation of BAX* cannot be fully compensated for by APRIL, which explains the disconnect of that data-derived model parameterization with our cell-survival data (Figure 2E). Hence, we concluded that APRIL- and ST2-driven regulation of BAX-dependent apoptosis alone is insufficient to
explain the observed survival curves, and rather, additional regulatory mechanisms must be considered.

Figure 2. A mechanistic model quantifies the BAX-dependent apoptosis network in plasma cells. (A) Geometric mean of measured core proteins in APRIL/ST2/APRIL + ST2 environments normalized to the respective concentration without stimulus (Medium) (n = 6 biological replicates). (B) Ratios of indicated proteins taken from (A) after normalization to Medium condition. (C) Model scheme: APRIL- and ST2-induced PI3K signal via NF-κB and FoxO, thereby affecting BCL-2 family protein abundance data, as shown in panel A. The model includes pro-apoptotic proteins BIM and NOXA (red) and anti-apoptotic proteins BCL-2 and MCL-1 (green). BAX* denotes activated BAX. (D) Protein ratios (see A) fitted to the model shown in panel B (χ² = 0.001). Error bars represent standard deviation. (E) Model fit to survival kinetics (Figure 1B) after fitting the protein ratios (χ² = 27.12). (F) Time-course simulation of the mechanistic apoptosis model for different inputs as indicated.
Table 2. Parameter values used in the mathematical models.

| Parameter | Value | Unit | Role | Source |
|-----------|-------|------|------|--------|
| $a_{BCL-2}$ | 0.11 | - | Effect APRIL on $g_{BCL-2}$ | Fit |
| $s_{MCL-1}$ | 0.37 | - | Effect ST2 on $g_{MCL-1}$ | Fit |
| $s_{BCL-2}$ | 0.53 | - | Effect ST2 on $g_{BCL-2}$ | Fit |
| $s_{BIM}$ | 0.49 | - | Effect ST2 on $g_{BIM}$ | Fit |
| $s_{NOXA}$ | 0.40 | - | Effect ST2 on $g_{NOXA}$ | Fit |
| $\gamma$ | 0.43 | $d^{-1}$ | Max. effect size BAX* | Fit |
| $\kappa$ | 1.78 | - | Max. effect Caspase 12 | Fit |
| $\beta$ | 2.65 | - | Inhibition strength ST2 on Caspase 3,7 | Fit |
| $d_{MCL-1}$ | 16.4 | $d^{-1}$ | Decay rate MCL-1 | [31] |
| $d_{BCL-2}$ | 0.86 | $d^{-1}$ | Decay rate BCL-2 | [31] |
| $d_{BIM}$ | 5.94 | $d^{-1}$ | Decay rate BIM | [33] |
| $d_{NOXA}$ | 32.8 | $d^{-1}$ | Decay rate NOXA | [34] |
| $d_{BAX}$ | 1.38 | $d^{-1}$ | Decay rate BAX | [32] |
| $K_{d,3}$ | 2.0 | nM | Dissociation constant | [22] |
| $K_{d,4}$ | 22.0 | nM | Dissociation constant | [22] |
| $K_{d,5}$ | 40.0 | nM | Dissociation constant | [22] |
| $K_{d,6}$ | 2.50 | nM | Dissociation constant | [22] |
| $K_{d,7}$ | 68.0 | nM | Dissociation constant | [22] |
| $k^+$ | 0.17 | $\mu$M $d^{-1}$ | Complex association rate | - |
| $k_1$ | 43.2 | $\mu$M $d^{-1}$ | BAX activation rate | - |
| $k_2$ | 8.64 | $\mu$M $d^{-1}$ | BAX* deactivation rate | - |
| $g_{p,0}$ | 0.86 | $\mu$M $d^{-1}$ | Basal protein growth | - |
| $\alpha$ | 10.0 | - | Inhibition strength APRIL on Caspase 12 | - |
| $K_{BAX}$ | 200 | nM | Half-saturation constant BAX-half-life | - |

3.2. Direct Regulation of Caspase Proteins Is Required for Effective Control

Caspases are not only mediators, but also critical regulators of apoptosis [35,36], and our recent data suggest that APRIL and ST2 have different roles in their regulation [12]. Specifically, we found that ST2-induced PI3K inhibits caspases 3 and 7, whereas APRIL-induced NF-kB inhibits the ER-stress-induced apoptosis mediated via caspase 12. Therefore, we supplemented our core model of BAX-dependent apoptosis by considering a network of caspase regulation (Figure 3A) (Methods). To specify the model, we added the two new fitting parameters describing the extended caspase network, and we found that this extended model indeed captures the individual and combined effects of APRIL and ST2 (Figure 3B,C). In particular, in contrast to the BAX core model, we obtained good results fitting the new caspase-related parameters to the plasma cell survival data (Figure 3C).

We could previously show that targeted inhibition of caspases had pronounced effects on plasma cell survival [12]. The successful data annotation gave us the opportunity to quantify the model dependency on these signaling pathways, as well as the effects of BCL-2-family members (Figure 3D and Supplementary Figure S3). As expected, the analysis showed strong effects for the regulation of caspase 3/7. That is in agreement with our previous data and with the intuition gained from Figure 2E, that direct regulation of caspase 3/7 through the ST2/PI3K pathway is required to counteract the pro-apoptotic role of ST2 within the BAX-dependent apoptosis pathway. Furthermore, our previous experiments have revealed quantitative effects in response to partial inhibition of PI3K and NF-kB [12]. Indeed, model simulations indicated a gradual response to PI3K and NF-kB, in contrast to a rather all-or-none type of regulation in the case of apoptotic proteins. Regulation of NF-kB turned out to have the largest effect on plasma cell lifespan (Figure 3E), also in line with our previous experiments.

Taken together, our analysis suggests that a unified description of the two considered data sets requires consideration of both BAX-dependent and BAX-independent regulation of caspases via both APRIL/NF-kB and ST2/PI3K.
Figure 3. Unifying the data sets on MCL-2 family members and plasma cell survival data requires direct regulation of caspases. (A) Model scheme, combination of the mechanistic mitochondrial apoptosis model (see Figure 2B) with ER-stress-induced caspase activation. (B,C) Combined model fit to protein data and survival kinetics ($\chi^2 = 0.152$). Error bars represent standard deviation. (D) Effect on half-life for simulated partial inhibition or overexpression of BAX/BCL-2-family proteins and caspases 3, 7, and 12. Parameters were varied by one order of magnitude with respect to the best-fit parameter value. (E) Effect of quantitative inhibition or overexpression of NF-κB, PI3K, and apoptotic regulators on half-life. Parameters were varied as 2-, 5-, or 10-fold change with respect to the best-fit parameter value.
3.3. Full Model Topology Is Essential to Describe Plasma Cell Survival

To further test whether our proposed model topology was necessary to describe all available data, we derived a set of sub-models lacking one or more components of the full model (Figure 4A). For each possible combination, we fitted the model to the available data and compared the fitting result to the original model fit (Figures 4B and S4). The full model had clearly the smallest fitting error ($\chi^2$), and models lacking regulatory effects of either APRIL, ST2, or both on caspase activity all provided similar fitting quality (Figure 4B). For a refined model comparison, we employed Akaike’s information criterion (AIC) (Figure 4C), a well-established metric for comparing models with differing numbers of fitting parameters [37]. AIC values lack a direct interpretation, and thus we only consider differences between models (−ΔAIC), and here we show −ΔAIC in relation to the model with poorest fit quality (Figure 4C). A difference of ΔAIC > 2 is usually regarded as significant, and therefore, our analysis clearly rules out all sub-models (Figure 4C). Nevertheless, the ΔAIC representation can also be regarded as a ranking of the most critical model components for explanation of the available data. As such, it is intriguing that in our model, ST2-driven regulation of caspase 3/7 is the most critical individual factor (panel (iv) in Figure 4A,C), even exceeding the effect of by-passing caspase regulation completely (panel (vi)). Hence, our model analysis supports both a strong role for BAX-independent caspase regulation and the critical need of ST2-derived signals for effective regulation of plasma cell survival.

Figure 4. All considered regulatory processes are required to explain the data. (A) Different hypothetic network topologies (ii–vi) as submodules of the model shown in (3A), here presented as a condensed version (i). Abbreviations: M2: Model 2; A: APRIL; S: ST2; C12: Caspase 12; C3/7: Caspase 3, Caspase 7. Model components removed from the full model are shown in red. (B) goodness-of-fit (1/root-mean-squared error) for each submodel (ii–vi). (C) Akaike information criterion (−ΔAIC) for each sub-model compared to the full model (i), where the model with smallest −ΔAIC is used as a reference and set to 0.

4. Discussion

In this work, we developed a mathematical model describing the survival of plasma cells in the bone marrow. We used the model to unify two acquired data sets, namely, abundance of pro- and anti-apoptotic proteins and plasma cell survival kinetics in the presence of the soluble factor APRIL and/or stromal ST2 cells as cell-contact-dependent survival signal. In the annotated model, the balance of survival proteins is a critical factor for the lifespan of plasma cells. Hence, we found that a combination of direct caspase regulation together with regulation of BAX-dependent pathways is essential to explain all available data. Furthermore, perturbation analysis of the model largely recovered previously established [12] effects of targeted inhibition experiments of caspases as well as NF-κB/PI3K signaling.
A characteristic property of plasma cells is the contribution of the endoplasmic reticulum (ER) to apoptosis regulation [13,38]. Since plasma cells as the primary antibody-secreting cell type produce vast amounts of proteins, they experience high ER-stress due to protein miss-folding. In plasma cells, BAX was not only found in the mitochondrial membrane but also localized at the ER [13]. We could recently show that the plasma cell microenvironment, composed of stromal cell contact and the cytokine APRIL, counteracts the activation of caspases 3 and 7 and caspase 12, respectively [12]. Caspases 3 and 7, that are activated upon mitochondrial stress [35], are regulated by PI3K signaling upon cell contact to stromal cells. Activation of the ER-associated caspase 12 is inhibited by APRIL signaling via the NF-κB pathway [12]. Here, our model simulations further supported that finding of differential regulation of caspases by APRIL and ST2, since without such additional flexibility the model was not able to explain both the apoptosis kinetics and the protein abundance data. For therapy, targeted depletion of memory plasma cells has been proposed as a promising strategy in autoimmune diseases such as lupus erythematosus [2].

On the other hand, memory plasma cells can provide long-lasting protection against infections, as recently demonstrated for mild SARS-CoV2 infections in humans [39]. The lifespan of immune cell populations is tightly controlled and is a critical property in a range of inflammatory processes, as shown previously in the context of selective expansion of lymphocyte subtypes [40,41] and NK cell subpopulations [42], amongst others. Therefore, a better quantitative understanding of the regulatory processes controlling the lifespan of memory plasma cells and other immune cell types will be critical for optimized targeted therapy and personalized medicine approaches.

The regulatory networks driving T-cell and B-cell differentiation and transition to memory cell types have been widely studied by combined computational and mathematical modeling studies. Such efforts are still rare in the analysis of immunologic cell death decisions and specifically in plasma cell biology. A recent study focused on the generation and composition of the survival niche [43], and a previous review estimated the long-term development of the pool of available memory plasma cells [44]. Here, using cultured plasma cells as a model system, we developed a fully annotated mathematical model of apoptosis regulation in memory plasma cells. This work may set the stage for further quantitative and mechanistic analyses of the differential regulation of apoptosis pathways in specific tissue and immune cell types.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11091547/s1, Figure S1: Plasma cell survival kinetics for individual experiments; Figure S2: Protein ratio and half-life prediction give good fit results for individual fits but not for both fits combined; Figure S3: Effect on BAX activation for simulated knockdown or overexpression of BAX/BCL-2 family-proteins.; Figure S4: Model fits for protein ratio and half-life for different model versions; Text S1: Detailed description of the mathematical model [20,45–48].

**Author Contributions:** Conceptualization, A.R., H.-D.C. and K.T.; Formal analysis, P.B. and G.G.; Investigation, P.B., R.C., G.G., S.H. and K.T.; Writing—original draft, P.B. and K.T.; Writing—review and editing, R.C. and H.-D.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Leibniz association (Best-minds program, to K.T.), the Leibniz ScienceCampus Chronic inflammation, the Deutsche Forschungsgemeinschaft (TH 1861/4-1 to K.T. and SFB TERRA 130 P16 to H.D.C. and A.R.), and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777357 to H.D.C. and A.R. H.D.C. is supported by the Dr. Rolf M. Schwiete Foundation.

**Institutional Review Board Statement:** All experiments were performed according to German law for animal protection and with the permission from the local veterinary offices, and in compliance with the guidelines of the Institutional Animal Care and Use Committee. The animal experiments were performed within the animal studies H007015 and G008-13.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data are contained within the article or supplementary material.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Khodadadi, L.; Cheng, Q.; Radbruch, A.; Hiepe, F. The Maintenance of Memory Plasma Cells. *Front. Immunol.* 2019, 10, 721. [CrossRef] [PubMed]

2. Hiepe, F.; Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. *Nat. Rev. Nephrol.* 2016, 12, 232–240. [CrossRef] [PubMed]

3. Maschmeyer, P.; Chang, H.-D.; Cheng, Q.; Mashreghi, M.-F.; Hiepe, F.; Alexander, T.; Radbruch, A. Immunological memory in rheumatic inflammation—A roadblock to tolerance induction. *Nat. Rev. Rheumatol.* 2021, 17, 291–305. [CrossRef] [PubMed]

4. Nutt, S.L.; Hodgkin, P.D.; Tarlinton, D.M.; Corcoran, L.M. The generation of antibody-secreting plasma cells. *Nat. Rev. Immunol.* 2015, 15, 160–171. [CrossRef] [PubMed]

5. Chu, V.T.; Berek, C. The establishment of the plasma cell survival niche in the bone marrow. *Immunol. Rev.* 2013, 251, 177–188. [CrossRef]

6. Manz, R.A.; Thiel, A.; Radbruch, A. Lifetime of plasma cells in the bone marrow. *Nature* 1997, 388, 133–134. [CrossRef]

7. DiLillo, D.J.; Hamaguchi, Y.; Ueda, Y.; Yang, K.; Uchida, J.; Haas, K.M.; Kelsoe, G.; Tedder, T.F. Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice. *J. Immunol.* 2008, 180, 361–371. [CrossRef]

8. Benson, M.J.; Dillon, S.R.; Castigl, E.; Geha, R.S.; Xu, S.; Lam, K.-P.; Noelle, R.J. Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL. *J. Immunol.* 2008, 180, 3655–3659. [CrossRef]

9. Landsverk, O.J.B.; Snir, O.; Casado, R.B.; Richter, L.; Mold, J.E.; R.; Paulsen, V.; Yaqub, S.; Aandahl, E.M.; et al. Antibody-secreting plasma cells persist for decades in human intestine. *J. Exp. Med.* 2017, 214, 309–317. [CrossRef]

10. Zehentmeier, S.; Roth, K.; Cseresnyes, Z.; Sercan, Ö.; Horn, K.; Niesner, R.A.; Chang, H.-D.; Radbruch, A.; Hauser, A.E. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. *Eur. J. Immunol.* 2014, 44, 2306–2317. [CrossRef]

11. Hoyer, B.F.; Moser, K.; Hauser, A.E.; Peddinghaus, A.; Voigt, C.; Eilat, D.; Radbruch, A.; Hiepe, F.; Manz, R.A. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. *J. Exp. Med.* 2004, 199, 1577–1584. [CrossRef] [PubMed]

12. Cornelis, R.; Hahne, S.; Taddeo, A.; Petkau, G.; Malko, D.; Durek, P.; Thiem, M.; Heiberger, L.; Peter, L.; Mohr, E.; et al. Stromal Cell-Contact Dependent PI3K and APRIL Induced NF-κB Signaling Prevent Mitochondrial- and ER Stress Induced Death of Memory Plasma Cells. *Cell Rep.* 2020, 32, 107982. [CrossRef] [PubMed]

13. Pelletier, N.; Casamayor-Pallejà, M.; De Luca, K.; Mondière, P.; Saltel, F.; Jurdic, P.; Bella, C.; Genestier, L.; Defrance, T. The Endoplasmic Reticulum Is a Key Component of the Plasma Cell Death Pathway. *J. Immunol.* 2006, 176, 1340–1347. [CrossRef] [PubMed]

14. Fussenegger, M.; Bailey, J.E.; Varner, J. A mathematical model of caspase function in apoptosis. *Nat. Biotechnol.* 2000, 18, 768–774. [CrossRef] [PubMed]

15. Spencer, S.L.; Sorger, P.K. Measuring and modeling apoptosis in single cells. *Cell* 2011, 144, 926–939. [CrossRef]

16. Goldstein, J.C.; Waterhouse, N.J.; Juin, P.; Evan, G.I.; Green, D.R. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. *Nat. Cell Biol.* 2000, 2, 156–162. [CrossRef]

17. Rehm, M.; Düßmann, H.; Jänicke, R.U.; Tavare, J.M.; Kögel, D.; Prehn, J.H.M. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process: Role of caspase-3. *J. Biol. Chem.* 2002, 277, 24506–24514. [CrossRef]

18. Eissing, T.; Conzelmann, H.; Gilles, E.D.; Allgöwer, F.; Bullinger, E.; Scheurich, P. Bistability analyses of a caspase activation model for receptor-induced apoptosis. *J. Biol. Chem.* 2004, 279, 36892–36897. [CrossRef]

19. Legewie, S.; Blüthgen, N.; Herzl, H. Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. *PLoS Comput. Biol.* 2006, 2, 1061–1073. [CrossRef]

20. Chen, C.; Cui, J.; Lu, H.; Wang, R.; Zhang, S.; Shen, P. Modeling of the role of a Bax-activation switch in the mitochondrial apoptosis decision. *Biosph. J.* 2007, 92, 4304–4315. [CrossRef]

21. McKenna, S.; García-Gutierrez, L.; Matallanas, D.; Fey, D. BAX and SMAC regulate bistable properties of the apoptotic caspase system. *Sci. Rep.* 2021, 11, 3272. [CrossRef] [PubMed]

22. Hantusch, A.; Brunner, T.; Frickey, T.; Rehm, M. Bcl-2-Ome-a database and interactive web service for dissecting the Bcl-2 interactome. *Cell Death Differ.* 2017, 24, 192. [CrossRef]

23. Hatzoglou, A.; Roussel, J.; Bourgeade, M.-F.; Rogier, E.; Madry, C.; Inoue, J.; Devergne, O.; Tsapis, A. TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, e-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase. *J. Immunol.* 2000, 165, 1322–1330. [CrossRef]

24. Chu, V.T.; Fröhlich, A.; Steinhauser, G.; Scheel, T.; Roch, T.; Fillatreau, S.; Lee, J.J.; Löhnig, M.; Berek, C. Eosinophils are required for the maintenance of plasma cells in the bone marrow. *Nat. Immunol.* 2011, 12, 151–159. [CrossRef]
25. O’Connor, B.P.; Raman, V.S.; Erickson, L.D.; Cook, W.J.; Weaver, L.K.; Ahonen, C.; Lin, L.-L.; Mantechv, G.T.; Bram, R.J.; Noelle, R.J. BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells. J. Exp. Med. 2004, 199, 91–97. [CrossRef] [PubMed]

26. Van Spriel, A.B.; De Keijzer, S.; Van Der Schaaf, A.; Gartlan, K.H.; Sofi, M.; Light, A.; Linssen, P.C.; Boezeman, J.B.; Zuidscherwoude, M.; Reinersen-Beerens, I.; et al. The tetraspanin CD37 orchestrates the α4β1 integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci. Signal. 2012, 5, ra82. [CrossRef]

27. Cosentino, K.; Garcia-Sáez, A.J. Bax and Bak Fores: Are We Closing the Circle? Trends Cell Biol. 2017, 27, 266–275. [CrossRef] [PubMed]

28. Peperzak, V.; Vikström, I.; Walker, J.; Glaser, S.P.; Coquery, C.M.; Erickson, L.D.; Mackay, F.; Strasser, A.; et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 2013, 14, 290–297. [CrossRef]

29. Gomez-Bougie, P.; Bataille, R.; Amiot, M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur. J. Immunol. 2004, 34, 3156–3164. [CrossRef]

30. Nakajima, W.; Hicks, M.A.; Tanaka, N.; Krystal, G.W.; Harada, H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis. 2014, 5, e1052. [CrossRef]

31. Rooswinkel, R.W.; Van De Kooij, B.; De Vries, E.; Paauwe, M.; Braster, R.; Verheij, M.; Borst, J. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood 2014, 123, 2806–2815. [CrossRef] [PubMed]

32. Cao, X.; Deng, X.; May, W.S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 2003, 102, 2605–2614. [CrossRef] [PubMed]

33. Meller, R.; Cameron, J.A.; Torrey, D.J.; Clayton, C.E.; Ordonez, A.N.; Henshall, D.C.; Minami, M.; Schindler, C.K.; Saugstad, J.A.; Simon, R.P. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons. J. Biol. Chem. 2006, 281, 7429–7436. [CrossRef] [PubMed]

34. Dengler, M.A.; Weibacher, A.; Gutekunst, M.; Staiger, A.M.; Vöhringer, M.C.; Horn, H.; Ott, G.; Aulitzky, W.E.; Van Der Kuip, H. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: A potential Achilles’ heel in mantle cell lymphoma. Cell Death Dis. 2014, 5, e1013. [CrossRef]

35. Lakhani, S.A.; Masud, A.; Kuida, K.; Porter, G.A.; Booth, C.J.; Mehal, W.Z.; Inayat, I.; Flavell, R.A. Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science 2006, 311, 847–851. [CrossRef]

36. Nakagawa, T.; Zhu, H.; Morishima, N.; Li, E.; Xu, J.; Yankner, B.A.; Yuan, J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 2000, 403, 98–103. [CrossRef]

37. Cavanaugh, J.E.; Neath, A.A. The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements. Wiley Interdiscip. Rev. Comput. Stat. 2019, 11, 1460. [CrossRef]

38. Gass, J.N.; Gurn, K.E.; Srburi, R.; Brewer, J.W. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol. 2004, 25, 17–24. [CrossRef]

39. Turner, J.S.; Kim, W.; Kalaidina, E.; Goss, C.W.; Rauseo, A.M.; Schmitz, A.J.; Hansen, L.; Haile, A.; Klebert, M.K.; Pusic, I.; et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 2021, 595, 421–425. [CrossRef]

40. Gett, A.V.; Hodgkin, P.D. A cellular calculus for signal integration by T cells. Nat. Immunol. 2000, 1, 239–244. [CrossRef]

41. Heinzel, S.; Binh Giang, T.; Kan, A.; Marchingo, J.M.; Lye, B.K.; Corcoran, L.M.; Hodgkin, P. A Myc-dependent division timer complements a cell-death timer to regulate T cell and B cell responses. Nat. Immunol. 2017, 18, 96–103. [CrossRef] [PubMed]

42. Hammer, Q.; Rückert, B.; Erden, S.; Hambleton, A.; Dürk, P.; Heinrich, F.; Gasparoni, G.; Babic, M.; Tomic, A.; et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat. Immunol. 2018, 19, 453–463. [CrossRef] [PubMed]

43. Mohr, M.; Hoffs, D.; Seckinger, A.; Marciniak-Czochra, A. Quantification of plasma cell dynamics using mathematical modeling. R. Soc. Open Sci. 2018, 5, 170759. [CrossRef] [PubMed]

44. Höfer, T.; Muehlinghaus, G.; Moser, K.; Yoshida, T.; Mei, H.E.; Hebel, K.; Hauser, A.E.; Hoyer, B.; Lugner, E.O.; Dörner, T.; et al. Adaptation of humoral memory. Immunol. Rev. 2006, 211, 295–302. [CrossRef] [PubMed]

45. Westphal, D.; Dewson, G.; Czabotar, P.E.; Kluck, R.M. Molecular biology of BAX and BAK activation and action. BBA Mol. Cell Res. 2011, 1813, 521–531. [CrossRef] [PubMed]

46. Westphal, D.; Kluck, R.M.; Dewson, G. Building blocks of the apoptotic pore: How BAX and BAK are activated and oligomerize during apoptosis. Cell Death Differ. 2014, 21, 196–205. [CrossRef]

47. Du, H.; Wolf, J.; Schafer, B.; Moldoveanu, T.; Chipuk, J.E.; Kuwana, T. BH3 domains other than BIM and BID can directly activate BAX/BAK. J. Biol. Chem. 2011, 286, 491–501. [CrossRef]

48. Czabotar, P.E.; Lessene, G.; Strasser, A.; Adams, J.M. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 2014, 15, 49–63. [CrossRef]